edoc

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder : a randomized, open-label clinical trial (EUFEST)

Davidson, Michael and Galderisi, Silvana and Weiser, Mark and Werbeloff, Nomi and Fleischhacker, Wolfgang W. and Keefe, Richard S. and Boter, Han and Keet, Ireneus P. M. and Prelipceanu, Dan and Rybakowski, Janusz K. and Libiger, Jan and Hummer, Martina and Dollfus, Sonia and López-Ibor, Juan J. and Hranov, Luchezar G. and Gaebel, Wolfgang and Peuskens, Joseph and Lindefors, Nils and Riecher-Rössler, Anita and Kahn, René S.. (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder : a randomized, open-label clinical trial (EUFEST). American journal of psychiatry, 166. pp. 675-682.

[img] PDF - Published Version
Restricted to Repository staff only

206Kb

Official URL: http://edoc.unibas.ch/dok/A6004565

Downloads: Statistics Overview

Abstract

OBJECTIVE: Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. METHODS: Subjects were 498 patients with schizophreniform disorder or first-episode schizophrenia who were randomly assigned to open-label haloperidol (1 to 4 mg/day [N=103]), amisulpride (200 to 800 mg/day [N=104]), olanzapine (5 to 20 mg/day [N=105]), quetiapine (200 to 750 mg/day [N=104]), or ziprasidone (40 to 160 mg/day [N=82]). The Rey Auditory Verbal Learning Test, Trail Making Test Part A and Part B, WAIS Digit Symbol Test, and Purdue Pegboard Test were administered at baseline and the 6-month follow-up evaluation. RESULTS: Compared with scores at baseline, composite cognitive test scores improved for all five treatment groups at the 6-month follow-up evaluation. However, there were no overall differences among the treatment groups. In addition, there was a weak correlation between the degree of cognitive improvement and changes in Positive and Negative Syndrome Scale scores. CONCLUSION: Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. The magnitude of improvement does not differ between treatment with haloperidol and treatment with second-generation antipsychotics. Moreover, cognitive improvement is weakly related to symptom change.
Faculties and Departments:03 Faculty of Medicine > Bereich Psychiatrie (Klinik) > Erwachsenenpsychiatrie UPK > Erwachsenenpsychiatrie (Riecher-Rössler)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Psychiatrie (Klinik) > Erwachsenenpsychiatrie UPK > Erwachsenenpsychiatrie (Riecher-Rössler)
UniBasel Contributors:Riecher-Rössler, Anita
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Psychiatric Association
Note:Publication type according to Uni Basel Research Database: Journal article
Language:English
Related URLs:
Identification Number:
Last Modified:06 Oct 2017 14:57
Deposited On:24 May 2013 09:01

Repository Staff Only: item control page